Racial Difference in Efficacy of Golimumab in Ulcerative Colitis.

ABSTRACT:

Background

Observational studies have described racial differences in inflammatory bowel disease (IBD) genetics, clinical manifestations, and outcomes. Whether race impacts response to biologics in IBD is unclear. We conducted a post hoc analysis of phase 2 and 3 randomized clinical trials in ulcerative colitis to evaluate the effect of race on response to golimumab.

Methods

We analyzed pooled individual-level data from induction and maintenance trials of golimumab through the Yale Open Data Access Project. The primary outcome was clinical response. Secondary outcomes were clinical remission and endoscopic healing. Multivariable logistic regression was performed comparing White vs racial minority groups (Asian, Black, or other race), adjusting for potential confounders.

R

SUBMITTER: Greywoode R 

PROVIDER: S-EPMC10233400 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature